Revealing the most promising drugs
The newly published Pharma Matters report—The Ones to Watch October-December 2008—reveals the most promising drugs changing clinical phase, receiving approval and launched this quarter.
Pharmaceutical innovators remain committed to their pipelines, no matter what the economic climate. Our lists of promising drugs this quarter include potential large-population treatments for cancer, HIV infection, asthma and osteoporosis, among others. But we also continue to see a number of promising niche, ‘specialty’ pharmaceuticals for small patient populations.
MGI Pharma, Genzyme, Eli Lilly, GlaxoSmithKline and Abbott/Solvay are responsible for the five most promising drugs launched or receiving approval.
The five most promising drugs entering Phase 3 trials are from Gene Signal, Daiichi Sankyo, TopoTarget, Indevus and Renovo.
Download The Ones To Watch October-December 2008 (PDF)
You can discover which other companies – and which drugs – made the top five in each category by subscribing to receive the latest and future editions of the Pharma Matters reports free every quarter.
Further reading
Download The Ones To Watch October-December 2008 (PDF)
Subscribe free to receive the latest and future editions of the Pharma Matters reports every quarter.
Was this article useful?
Download a PDF of all
February 2009's
KnowledgeLink articles
Register now for KnowledgeLink, our customizable email newsletter that delivers expert insight on:
- Global innovation
- Information professional development
- Intellectual property
- Pharmaceutical knowledge
- Scientific research